Mahdi Basha, DO
Ophthalmology · Fraser, MINPI 1396900379
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AbbVie at 55.4% of the total. Reporting peaked in 2021 at $7,462 and has fallen 89.4% since, to $793 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $94.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Alcon$4K
- Alcon Research LLC$1K
- Ivantis, Inc$567
- Novartis$161
- Bausch & Lomb, A Division Of Bausch Health US, LLC$121
- plus $1K from 21 others
Across 636 payments — averaging $3478.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.7M
- Glaukos Corporation$207K
- Alcon Research LLC$178K
- Oyster Point Pharma, Inc.$84K
- Ivantis, Inc$26K
- Ocular Therapeutix, Inc.$3K
What the payments were for
- Consulting fees$1,0007%
- Speaking & faculty fees$5,52637%
- Travel & lodging$3,32922%
- Food & beverage$4,80532%
- Gifts$1001%
- Entertainment$921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $8,235 |
| Alcon | 58 | $3,723 |
| Alcon Research LLC | 1 | $1,008 |
| Ivantis, Inc | 6 | $567 |
| Novartis | 10 | $161 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $121 |
| Oyster Point Pharma, Inc. | 6 | $120 |
| Aerie Pharmaceuticals, Inc. | 4 | $112 |
| Rxsight Inc | 5 | $100 |
| Glaukos Corporation | 2 | $97 |
| Optos, Inc. | 1 | $92 |
| Amgen(2 entities) | 5 | $79 |
| Bausch & Lomb Americas Inc. | 4 | $75 |
| Thea Pharma Inc. | 3 | $58 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Akorn Operating Company LLC | 2 | $36 |
| Lombart Brothers, Inc. | 1 | $31 |
| Eyepoint US, Inc. | 2 | $28 |
| NEW World Medical,inc. | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 2 | $24 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Akorn, Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Spark Therapeutics, Inc. | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$6,839
- Hydrus Microstent$583
- Hydrus$293
- Centurion$147
- ORA$144
- AcrySof IQ PanOptix$139
- ORA System VerifEye$133
- Clareon PanOptix Pro$125
- NGENUITY$115
- ReSTOR$101
How this compares
$14,852 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 191 | $76,277 |
| RestasisCyclosporine | 62 | $61,273 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $38,389 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 177 | $34,061 |
| Prednisolone Acetate | 607 | $26,709 |
| Cyclosporine | 60 | $26,587 |
| Latanoprost | 1,452 | $21,917 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 63 | $14,907 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 537 | $12,485 |
| VyzultaLatanoprostene Bunod | 32 | $12,431 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $12,167 |
| Travoprost | 60 | $12,054 |
| Loteprednol Etabonate | 63 | $10,503 |
| Fluorometholone | 107 | $8,965 |
| Difluprednate | 71 | $8,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $8,235 | $175,940371 claims |
| AlconSimbrinza | $3,723 | $14,90763 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $75 | $12,43132 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $112 | $12,16726 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $121 | $10,50363 claims |
| Akorn, Inc.Betimol | $18 | $2,74514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Fraser
- Joseph TanFraser$11K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.